miR-199 was reported to have lower expression in ovarian cancer, and this miRNA inhibited the related gene pathway by blocking the activation of the c-MET, HIF1-alpha HIF2-beta, and IKK-beta proteins, and thus might be a therapeutic target [44–46]. This evidence concerns the gene MET and ovarian cancer.